glecaprevir/pibrentasvir vs losartan
Side-by-side comparison of glecaprevir/pibrentasvir and losartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.5 Drugs with No Observed Clinically Significant Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan.
Recommendation: You can continue taking both medications at your current doses.
Mavyret
Cozaar
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Losartan is a medicine that lowers blood pressure. It can also help prevent strokes in some people with high blood pressure and an enlarged heart.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Losartan is used to treat high blood pressure in adults and children over 6 years old. Lowering blood pressure reduces the risk of strokes and heart attacks. It is also used to treat kidney problems in people with type 2 diabetes and high blood pressure. Losartan can also reduce the risk of stroke in patients with high blood pressure and an enlarged left ventricle of the heart.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
Losartan blocks a substance in your body that tightens blood vessels. This helps blood vessels relax, which lowers blood pressure. It also helps the kidneys work better in people with diabetes.
- • Headache
- • Feeling tired
- • Nausea
- • Dizziness
- • Upper respiratory infection
- • Nasal congestion
- • Back pain
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
- Tiredness 11,852
- Diarrhea 9,868
- Feeling sick to your stomach 9,206
- Difficulty breathing 8,439
- Feeling lightheaded 7,999
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Losartan can harm your unborn baby, even causing death. If you are pregnant or plan to become pregnant, tell your doctor right away. Stop taking losartan as soon as you know you are pregnant.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Do not take losartan if you are pregnant. It can cause serious harm or death to the developing fetus. If you are breastfeeding, talk to your doctor about whether losartan is right for you.
Also Compare, Nearby Drugs
Compare losartan with
How to Read This glecaprevir/pibrentasvir vs losartan Comparison
glecaprevir/pibrentasvir is classified in the NS3/4A/NS5A Inhibitor (HCV) drug class, while losartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, glecaprevir/pibrentasvir has 7,019 submissions while losartan has 47,364. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to there are no known significant interactions between these two medications.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between glecaprevir/pibrentasvir and losartan - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.